Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

Status:	Recruiting
Conditions:	Cancer, Neurology
Therapuetic Areas:	Neurology, Oncology
Healthy:	No
Age Range:	Any
Updated:	3/23/2019
Start Date:	August 2010
End Date:	December 2019
Contact:	Jonathan Finlay, MD
Email:	Jonathan.Finlay@nationwidechildrens.org
Phone:	614-722-4087

A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoietic Stem Cell Rescue (AuHSCR) for Patients With Recurrent or Progressive Intracranial Germ Cell Tumors

This study will look to see how well patients with relapsed or recurrent intracranial germ
cell tumors respond to the new combination of chemotherapy (in induction)of Gemcitabine,
Paclitaxel and Oxaliplatin (GemPOx) followed by consolidation chemotherapy and autologous
stem cell rescue.

Inclusion Criteria:

- ICGCT including pure germinoma and MMGCT.

- Patients with histologically proven germinoma and MMGCT, including endodermal sinus
tumor (yolk sac tumor), embryonal carcinoma, choriocarcinoma and mixed germ cell tumor
will be eligible for the study.

- Patients with mature/immature teratoma who have tumor marker elevations are eligible
on this study.

- Patient with ONLY mature and/or immature teratoma are ineligible in the absence of the
tumor marker elevations.

Exclusion Criteria:

- Patients with ICGCTs who are newly diagnosed are excluded from the study.

- Patients with the diagnosis of mature or immature teratoma in the absence of tumor
marker elevations are excluded from the study.

- Patients who are pregnant or breastfeeding are excluded from the study.

- Patients who have received previously a high dose chemotherapy regimen and autologous
transplant are excluded from this study.

- Patients who have received gemcitabine, oxaliplatin and/or paclitaxel are excluded
from this study.

We found this trial at

sites

Childrens Hospital Los Angeles

4650 Sunset Blvd
Los Angeles, California 90027

(323) 660-2450